This segment focuses on the research, development, and manufacturing of a diverse portfolio of vaccines targeting infectious diseases. Walvax employs advanced biotechnological methods to produce vaccines against meningitis, pneumococcal disease, influenza, and other prevalent diseases. R&D efforts include the development of novel vaccine candidates and the improvement of existing vaccine formulations to enhance immunogenicity and safety. Clinical trials are conducted to evaluate the efficacy and safety of these vaccines, ensuring regulatory compliance and market access. The company's manufacturing facilities adhere to stringent quality control standards to ensure the production of high-quality vaccines for both domestic and international markets. This segment aims to address unmet medical needs and improve public health outcomes through innovative vaccine solutions.

Walvax is actively engaged in the research and development of mRNA vaccine technology, particularly for respiratory viruses and emerging infectious diseases. This segment leverages cutting-edge mRNA design and delivery systems to create highly effective and rapidly deployable vaccines. Research efforts focus on optimizing mRNA stability, enhancing protein expression, and improving the immune response. Clinical studies are conducted to assess the safety and efficacy of mRNA vaccine candidates. The company has established a state-of-the-art mRNA vaccine industrial production plant to support large-scale manufacturing. This segment aims to provide innovative solutions for pandemic preparedness and address the evolving challenges of infectious disease control.